Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CryositeASX:CTE 70 Shiller PE Ratio is 59.00 as of Sep. 14, 2026, which is 50% above its 10-year median of 39.25. GuruFocus rates ASX:CTE with a GF Score™ of 70/100 and a GF Value™ of A$1.02 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 78 Medical Diagnostics & Research companies, Cryosite ranks worse than 83.33% on this metric.
As of today (2026-09-14), Cryosite's current share price is A$1.18. Cryosite's E10 for the fiscal year that ended in Jun26 was A$0.02. Cryosite's Shiller PE Ratio for today is 59.00.
The historical rank and industry rank for Cryosite's Shiller PE Ratio or its related term are showing as below:
ASX:CTE'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 3.2 Med: 39.25 Max: 124
Current: 59.61
During the past 13 years, Cryosite's highest Shiller PE Ratio was 124.00. The lowest was 3.20. And the median was 39.25.
ASX:CTE's Shiller PE Ratio is ranked worse than 83.33% of 78
companies
in the Medical Diagnostics & Research industry
Industry Median: 28.43
vs ASX:CTE: 59.61
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Cryosite's adjusted earnings per share data of for the fiscal year that ended in Jun26 was A$0.043. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is A$0.02 for the trailing ten years ended in Jun26.
Shiller PE for Stocks: The True Measure of Stock Valuation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Cryosite Shiller PE Ratio Related Terms
Cryosite Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Cryosite's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, NTRA: Shiller PE Ratio Comparison
For the Diagnostics & Research subindustry, Cryosite's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite Shiller PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Cryosite's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Cryosite's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite's E10 for the fiscal year that ended in Jun26 is calculated as:
For example, Cryosite's adjusted earnings per share data for the fiscal year that ended in Jun26 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Cryosite (ASX:CTE) has a Shiller PE Ratio of 59.00 as of Sep. 14, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Cryosite and its competitors. This is 50% above median its historical median of 39.25. Over the past decade, Cryosite's Shiller PE Ratio has ranged from 3.20 to 124.00. According to the industry distribution chart, Cryosite ranks #65 out of 78 companies in the Medical Diagnostics & Research industry, placing it in the top 83.3%.
Is Cryosite's Shiller PE Ratio too high?
Cryosite's current Shiller PE Ratio of 59.00 is 50% above median its 10-year median of 39.25. Over the past 10 years, this metric has ranged from a low of 3.20 to a high of 124.00. The Medical Diagnostics & Research industry median Shiller PE Ratio is 28.43. Cryosite's value of 59.00 is 107.5% above this industry median. Based on the distribution chart, Cryosite ranks #65 out of 78 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Cryosite has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Shiller PE Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #65 out of 78 companies for Shiller PE Ratio. This places Cryosite in the lower half of its industry. The industry median Shiller PE Ratio is 28.43. Cryosite's value of 59.00 is 107.5% above this benchmark. Historically, Cryosite's own Shiller PE Ratio has ranged from 3.20 to 124.00 over the past decade. While the company's 10-year median is 39.25 vs. the industry median of 28.43, Cryosite has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Medical Diagnostics & Research company?
The median Shiller PE Ratio among Medical Diagnostics & Research companies is 28.43, based on 78 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryosite's current Shiller PE Ratio of 59.00 is 107.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Cryosite and its competitors. For the Medical Diagnostics & Research industry, the median Shiller PE Ratio is 28.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current Shiller PE Ratio is 59.00, which is 50% above median its own 10-year median of 39.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$1.02, compared to a current price of A$1.18 — trading 15.7% above its estimated fair value. The current Shiller PE Ratio is 59.00, which is 50% above median its 10-year median of 39.25 and 107.5% above the Medical Diagnostics & Research industry median of 28.43. Cryosite's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Shiller PE Ratio is 59.00 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.18 is trading 15.7% above its estimated GF Value™ of A$1.02.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
Shiller PE Ratio: 59.00 (50% above median its 10-year median of 39.25)
GF Value™: A$1.02 vs. price of A$1.18 (15.7% above fair value)
Industry Position: 107.5% above the Medical Diagnostics & Research median (#65 of 78)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
70GF Score
Get the complete analysis for ASX:CTE
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
